Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
TAVR is Ready for Most Low-risk Patients
Author(s): Ahmad Jabri , Anas Alameh , Gennaro Giustino , et al Added: 1 year ago

Intervention

Vascular Disease and Surgery
Polygenic Risk Score Independently Predicts New-Onset Heart Failure
Added: 2 months ago Source:  Radcliffe Cardiology, Mirjam Boros
The global burden of heart failure (HF) remains a significant challenge for healthcare systems.² While clinical risk factors are well-established, the utility of genetic information in predicting incident HF has been less certain. A recent study investigated the ability of a heart failure polygenic risk score (HF PRS) to predict new-onset HF in individuals across the full spectrum of… View more

Heart Failure

Imaging & Diagnostics
EASD 2025 Highlights: Updates on Icosapent Ethyl and Cardiometabolic Risk
Author(s): Rahul Aggarwal , Dirk Müller-Wieland Added: 2 months ago
Filmed onsite at EASD 2025, this on-demand series features key insights from Prof Dirk Müller-Wieland and Dr Rahul Aggarwal to interpret the latest data on eicosapentaenoic acid(EPA), including the latest sub-analysis of the REDUCE-IT trial, whichanalysed the effectiveness of icosapent ethyl (IPE) on CV risk by triglyceride-glucose (TyG) index - an indicator of insulin resistance and risk of type… View more

Heart Failure

Prevention & Chronic Conditions
ESCHFA25: FINEARTS-HF: Finerenone Risk-Benefit Across Kidney Function
Author(s): Safia Chatur Added: 6 months ago
ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure… View more

Cardiovascular Renal Metabolic

Heart Failure
ACC 23: Inflammatory Risk from Statin-Treated Patients
Author(s): Paul M Ridker Added: 2 years ago
ACC.23/WCC - We are joined by Dr Paul Ridker (Brigham and Women’s Hospital, US) to discuss the findings from a collaborative analysis of 31,197 patients to assess inflammatory risk in statin-treated patients. The PROMINENT, REDUCE-IT and STRENGTH trials were each large contemporary trials which implemented guideline-directed medical therapy, the findings of which were pooled in this study. The… View more

Prevention & Chronic Conditions
EASD 23: Epidemiologic Trends & Disparities in Diabetes Risk Among LGBTQ+ Population
Author(s): Carl Streed Added: 2 years ago
EASD 2023 – Dr Carl G Streed (Boston University School of Medicine, US) joins us to summarise healthcare disparities among the LGBTQ+ population.In this interview, Dr Streed discusses the available evidence and explains the minority stress model. This model suggests that experiences of discrimination and stress contribute to worse health outcomes in the LGBTQ community. This can lead to mental… View more

Demographic

Prevention & Chronic Conditions
Liver Stiffness to Assess Central Venous Pressure in HF
Author(s): Nicolas Girerd Added: 6 months ago
ESC HF 25 - Outcomes from a study investigating liver stiffness measurement as a non-invasive method to assess central venous pressure showed immediate results at bedside obtained in >4 minutes, with the procedure easily performed by a trained nurse.Prof Nicolas Girerd (University Hospital of Nancy, Nancy, FR) discusses a pilot validation study investigating liver stiffness as a non-invasive… View more

Cardiovascular Renal Metabolic

Heart Failure
Martin Lowe
Dr Martin Lowe is a Consultant Cardiologist and Electrophysiologist, specialising in the treatment of arrhythmias in children with catheter ablation and pacemaker / defibrillator implantation.​ His research interests include ablation strategies in those with arrhythmias accompanying cardiomyopathy or congenital heart disease, risk stratification in patients and families predisposed to sudden… View more
BMI Affects NT-proBNP Risk Stratification in HFpEF
Added: 1 month ago Source:  Radcliffe Cardiology
Natriuretic peptides are key biomarkers used to risk-stratify patients with heart failure (HF), but current guideline thresholds do not typically account for body mass index (BMI).¹ A new pooled analysis suggests that these fixed thresholds may underestimate risk in patients with HF and higher BMI, questioning the one-size-fits-all approach.²This study was a participant-level pooled analysis of… View more

Cardiovascular Renal Metabolic

Electrophysiology & Arrhythmia